VANCOUVER, British Columbia , Aug. 22, 2024 /PRNewswire/ -- Rehabtronics, a leader in advancing neurostimulation technology, is pleased to announce that Health Canada has approved the Prelivia device, an innovative device designed to address the critical issue of tissue oxygenation, the primary cause of pressure injuries in immobile patients. Pressure injuries, also known as bedsores, impact millions of patients annually, resulting in serious complications and prolonged hospital stays.
According to recent data from the Canadian Institute for Health Information, the incidence of hospital-acquired pressure injuries (HAPI) has increased by 43% over the past four years (2018-2022) and continues to rise – making HAPIs the fastest growing hospital harm event. These injuries are also a frequent medical issue for individuals with paralysis and immobility, including those living with spinal cord injuries (SCI), chronic stroke, muscular sclerosis, Parkinson's, and the elderly, who are all at an elevated risk. "We are thrilled to receive Health Canada's approval for Prelivia," said Rahul Samant , CEO of Rehabtronics.
"As a Canadian business, this marks a significant milestone in our mission to improve patient outcomes and enhance the quality of care for those in Canada . With Prelivia, Canadian healthcare providers have a revolutionary new tool that enables them, for the first time, to intervene at the tissue ischemia phase of pressure injury development." The Prelivia device is based.